These mutational profiles have prompted the need to evaluate triple combination therapies: currently, triple therapy with dabrafenib+trametinib+panitumumab (anti-EGFR) is being evaluated in colorectal cancer with EGFR mutation (35, 43). This evidence concerns the gene EGFR and colorectal cancer.